Securities adjusted its outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $130 from $110 while maintaining an Outperform rating. The revision follows a series of positive developments reported by the medical device company,

Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.

Learn more about whether Boston Scientific Corporation or Penumbra, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.